Elmind Capital, LP

Position in AMLX — Amylyx Pharmaceuticals, Inc.

CIK 2052213 NEW YORK, NY

Position in AMLX

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$1,556,800

+$203,840 QoQ

Shares Held

112,000

0.0% QoQ

Ownership

0.101%

of shares outstanding

% of Portfolio

0.44%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2025

2 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

Elmind Capital, LP holds $21,005,300 across 4 Drug Manufacturers - Specialty & Generic names. AMLX ranks #3 (7.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	BCRX	Biocryst Pharmaceuticals Inc	1,000,000	$9,520,000
2	UTHR	UNITED THERAPEUTICS Corp	15,000	$8,894,700
3	AMLX	Amylyx Pharmaceuticals, Inc. This page	112,000	$1,556,800
4	SUPN	Supernus Pharmaceuticals, Inc.	20,000	$1,033,800

2 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,556,800	112,000	0.0%	Shares	Sole	2026-05-15
2025-12-31	$1,352,960	112,000	—	Shares	Sole	2026-02-17
No filing history on record for this holder in this stock.